Ultragenyx Angelman syndrome drug fails Phase 3 trial

Ultragenyx's experimental therapy for Angelman syndrome failed to show benefit over sham in a Phase 3 trial. The failure is a setback for the company's pipeline and for patients with the rare neurogenetic disorder. The result may impact Ultragenyx's stock and future development plans.